Spots Global Cancer Trial Database for Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

Official Title: Adderall-XR Versus Concerta For Cancer Treatment-Related Neurocognitive Sequelae And Depression In Pediatric Patients: A Randomized Phase II Study

Study ID: NCT00069927

Conditions

Depression

Neurotoxicity

Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

Adderall-XR®

Concerta®

Study Description

Brief Summary: RATIONALE: Stimulant drugs such as dextroamphetamine-amphetamine and methylphenidate may help improve memory, attention, and thinking problems caused by central nervous system (CNS) treatment for cancer, and may help decrease depression. PURPOSE: This randomized phase II trial is studying dextroamphetamine-amphetamine to see how well it works compared to methylphenidate in treating depression and problems with memory, attention, and thinking in children who have undergone CNS treatment for cancer. This trial will also study how often depression is seen and if these medications might help.

Detailed Description: OBJECTIVES: * Compare the response rates in pediatric cancer patients with treatment-related neurocognitive sequelae treated with dextroamphetamine-amphetamine (Adderall-XR®) vs methylphenidate (Concerta®). * Compare the durability of response at 12 weeks in patients who show a response at 3 weeks after treatment with these drugs. * Determine whether patients who have no response to one of these study drugs can respond to the other study drug. * Determine the prevalence of depression and possible response to neurostimulant therapy in this patient population. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral dextroamphetamine-amphetamine once daily for 3 weeks. Patients who achieve response (based on neurocognitive testing) continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm II after a 48-hour washout period. * Arm II: Patients receive oral methylphenidate once daily for 3 weeks. Responding patients continue treatment for a total of 12 weeks. Patients with no response after 3 weeks cross over to arm I after a 48-hour washout period. Depression and neurocognitive function are assessed at baseline, 3 weeks, and end of study. PROJECTED ACCRUAL: A total of 177 patients (approximately 88 per treatment arm) will be accrued for this study within 3 years.